Ir para o conteúdo principal

Cadrenal Therapeutics (NASDAQ: CVKD) — Perfil da empresa, notícias e dados financeiros

Logo de Cadrenal Therapeutics
CVKD Cadrenal Therapeutics
Cadrenal Therapeutics  primary media
Perfil da empresa

Cadrenal Therapeutics

Cadrenal Therapeutics (NASDAQ:CVKD) specializes in the discovery, development, and commercialization of innovative therapies for the treatment of cardiovascular diseases, adrenal disorders, and related areas. Its operations focus on advancing a pipeline of proprietary compounds through clinical development to address unmet medical needs in these therapeutic areas. Cadrenal Therapeutics is dedicated to improving patient outcomes through scientific excellence and robust clinical trial programs. The company’s objectives include delivering breakthrough treatments, expanding its portfolio through strategic collaborations, and ensuring the accessibility of its therapies to patients worldwide. Cadrenal Therapeutics is committed to excellence in research and development, aiming to become a key player in transforming patient care in its focus areas.

Resumo

Public USParticipação acionária
2022Ano de fundação
4Funcionários
Florida, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Cadrenal Therapeutics

  • Development of innovative cardiovascular medications aimed at enhancing patient outcomes and treatment experiences.
  • Research into novel therapeutic agents for the management of chronic heart conditions.
  • Advanced therapy development for rare cardiovascular diseases, focusing on unmet medical needs.
  • Collaboration with healthcare professionals and institutions to deliver educational programs and resources on cardiovascular health.
  • Implementation of cutting-edge technology in drug discovery processes to expedite the development of effective treatments.
  • Community outreach initiatives dedicated to raising awareness and support for individuals affected by cardiovascular diseases.

equipe executiva do Cadrenal Therapeutics

  • Quang X. PhamChairman & CEO
  • John P. SharpInterim CFO & Principal Accounting Officer
  • Jeffrey ColeChief Operating Officer

Principais indicadores financeiros

Resultados divulgados pela Cadrenal Therapeutics , em USD.

Cap. de mercado
2,9 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-4.9
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Cadrenal Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-13,5 mi-13,2 mi
0-11 mi-10,7 mi
0-7,6 mi-8,4 mi
—-2,7 mi-6,7 mi